BioNexus Gene Lab Corp. (BGLC) Revenue History
Annual and quarterly revenue from 2016 to present
BGLC Revenue Over Time (2016–2025)
BGLC Revenue Growth History
3 of 8 years with positive growth- FY2016 revenue growth
- N/A
- FY2017 revenue growth
- N/A
- FY2018 revenue growth
- +97.2%
- FY2019 revenue growth
- -40.2%
- FY2020 revenue growth
- +8872.0%
- FY2021 revenue growth
- +17.3%
- FY2022 revenue growth
- -18.2%
- FY2023 revenue growth
- -10.6%
- FY2024 revenue growth
- -2.7%
- FY2025 revenue growth
- -21.9%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $23K | -98.9% |
| Q4 2025 | $484K | -80.8% |
| Q3 2025 | $2.5M | -3.3% |
| Q2 2025 | $2.3M | +14.5% |
| Q1 2025 | $2.1M | -10.3% |
| Q4 2024 | $2.5M | +11.0% |
| Q3 2024 | $2.6M | +3.0% |
| Q2 2024 | $2.0M | -23.1% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown
BGLC's revenue distribution by segment and geography
By Geography
BGLC Revenue Analysis (2016–2025)
Current Revenue & Growth
As of June 25, 2026, BioNexus Gene Lab Corp. (BGLC) generated trailing twelve-month (TTM) revenue of $5.3 million, reflecting significant decline in growth of -98.9% year-over-year. The most recent quarter (Q1 2026) recorded $22,842 in revenue, down 95.3% sequentially.
Historical Growth Trajectory
BGLC's 5-year compound annual growth rate (CAGR) stands at -8.2%, indicating revenue contraction over this period. The 3-year CAGR of -12.1% is below the 5-year average, signalling a growth deceleration in recent years. BioNexus Gene Lab Corp.'s highest annual revenue of $13.4 million was recorded in 2021.
Peer Comparison
Compared to Healthcare sector peers — including QDEL (-3.9% YoY), CLOV (+48.4% YoY), and AEYE (+11.6% YoY) — BGLC has underperformed the peer group in revenue growth. Compare BGLC vs QDEL →
BGLC Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BGLCCurrent | $5M | -98.9% | -8.2% | -42.5% | |
 QDEL | $2.7B | -3.9% | +10.4% | -33.7% | |
 CLOV | $1.9B | +48.4% | +23.4% | -4.4% | |
 AEYE | $40M | +11.6% | +14.5% | -7.9% | |
 IDXX | $4.3B | +13.1% | +9.7% | 31.6% |
BGLC Historical Revenue Data (2016–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $7.4M | -21.9% | $1.1M | 14.6% | $-3,158,450 | -42.5% |
| 2024 | $9.5M | -2.7% | $1.3M | 13.6% | $-1,573,702 | -16.5% |
| 2023 | $9.8M | -10.6% | $1.3M | 13.6% | $-2,593,588 | -26.5% |
| 2022 | $10.9M | -18.2% | $1.3M | 11.5% | $-291,177 | -2.7% |
| 2021 | $13.4M | +17.3% | $2.2M | 16.4% | $1.1M | 7.9% |
| 2020 | $11.4M | +8872.0% | $1.7M | 15.1% | $1.3M | 11.2% |
| 2019 | $127K | -40.2% | $56K | 44.0% | $-275,705 | -217.2% |
| 2018 | $212K | +97.2% | $29K | 13.5% | $60K | 28.2% |
| 2017 | $108K | - | $79K | 73.2% | $-127,910 | -118.8% |
| 2016 | $0 | - | $0 | - | $-840 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BGLC — Frequently Asked Questions
Quick answers to the most common questions about buying BGLC stock.
Is BGLC's revenue growth accelerating or slowing?
BGLC revenue is declining -98.9% year-over-year. TTM revenue fell to $5M, contrasting with the 5-year CAGR of -8.2%. The reversal reflects either macro headwinds or company-specific challenges.
What is BGLC's revenue history from 2016 to 2026?
BioNexus Gene Lab Corp. (BGLC) revenue history spans 2016 to 2026. TTM revenue as of 2026 is $5M, growing at -98.9% YoY. The 5-year CAGR is -8.2%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is BGLC's long-term revenue growth rate (CAGR)?
BioNexus Gene Lab Corp.'s 5-year revenue CAGR of -8.2% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -98.9% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for BGLC.
Why does BGLC's quarterly revenue fluctuate?
BGLC quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. BioNexus Gene Lab Corp.'s revenue data from 2016 to 2026 shows full historical quarterly detail on this page.
How is BGLC's revenue distributed by segment?
BGLC reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does BGLC's revenue compare to industry peers?
BioNexus Gene Lab Corp. (BGLC) with TTM revenue of $5M and -98.9% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.